Core Viewpoint - The legal opinion issued by Beijing Guantao (Hangzhou) Law Firm confirms that Zhejiang Kang En Bei Pharmaceutical Co., Ltd.'s differentiated dividend distribution plan for the year 2024 complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [8]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's net profit of RMB 405,473,540.71 for 2024, with a 10% legal surplus reserve of RMB 40,547,354.07 being deducted [6][7]. - The company plans to distribute a cash dividend of RMB 1.50 (including tax) for every 10 shares to all shareholders, calculated based on the total share capital after excluding the shares held in the repurchase account [6][7]. Group 2: Share Repurchase Details - The company announced a share repurchase plan with a total fund of no less than RMB 200 million and no more than RMB 400 million, with the repurchase period set for six months from the board's approval date [4][5]. - As of July 21, 2024, the company completed the repurchase of 63,579,048 shares, accounting for 2.47% of the total share capital, with an average repurchase price of RMB 4.72 per share [5][6]. Group 3: Legal Compliance and Conclusion - The law firm confirms that the differentiated dividend distribution adheres to the Company Law, Securities Law, and other relevant regulations, ensuring that it does not harm the interests of the company and its shareholders [8]. - The legal opinion is intended solely for the purpose of the differentiated dividend distribution and must not be used for any other purpose without prior written consent from the law firm [3].

Core Viewpoint - The company has approved a differentiated profit distribution plan for the fiscal year 2024, which includes a cash dividend of 1.50 yuan per 10 shares for eligible shareholders [2][4]. Distribution Plan - The distribution will be based on a total share capital of 2,584,790,946 shares, excluding 63,579,048 shares held in the company's repurchase account, resulting in a base of 2,521,211,898 shares for the cash dividend calculation [2][3]. - The total cash dividend to be distributed amounts to 378,181,784.7 yuan (including tax) [2]. Dividend Calculation - The cash dividend per share is calculated to be approximately 0.1463 yuan after adjusting for the total share capital [3][5]. - The reference price for ex-dividend trading will be adjusted based on the formula provided, taking into account the cash dividend and the change in circulating shares [5]. Implementation Method - Cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch to registered shareholders as of the record date [5][6]. - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [5]. Taxation Information - Individual shareholders holding shares for over one year will be exempt from personal income tax on dividends, while those holding for less than one month will have their dividends fully taxed [7][8]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% withholding tax applied, resulting in a net cash dividend of 0.135 yuan per share [8][9]. Future Adjustments - Following the completion of the 2024 profit distribution, the company will adjust the exercise price of its stock option incentive plan in accordance with regulatory requirements [10].

北京观韬（杭州）律师事务所 关于浙江康恩贝制药股份有限公司 差异化分红事项的法律意见书 致：浙江康恩贝制药股份有限公司 北京观韬（杭州）律师事务所（以下简称"本所"）接受浙江康恩贝制药股份有 限公司（以下简称"公司"或"康恩贝"）委托，依据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公司股份回购规 则》（以下简称"《回购规则》"）、《律师事务所从事证券法律业务管理办法》《律 师事务所证券法律业务执业规则（试行）》等法律、行政法规、规范性文件及现行有 效的《公司章程》等规定，就公司 2024 年年度利润分配实施所涉及的差异化分红（以 下简称"本次差异化分红"）相关事宜出具法律意见书。 本所是依法注册具有执业资格的律师事务所，有资格就中国法律、法规、规范性 文件的理解和适用出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以前已经发 生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚 ...

证券代码：600572 证券简称：康恩贝 公告编号：2025-034 浙江康恩贝制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 A 股每股现金红利0.15元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/24 | － | 2025/6/25 | 2025/6/25 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 本次利润分配方案经浙江康恩贝制药股份有限公司（以下简称"公司""本公 司"）2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、分配方案 （一）发放年度：2024年年度 重要内容提示： 每股分配比例 （二）分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据中国证监会《上市公司股份回购规则 ...

Core Viewpoint - The legal opinion letter issued by Shanghai Dongfang Huayin Law Firm confirms that Zhejiang Kang En Bei Pharmaceutical Co., Ltd. has complied with relevant laws and regulations regarding the adjustment of the exercise price for its 2022 stock option incentive plan [1][8]. Group 1: Company Qualifications - The company is a legally established joint-stock company listed on the Shanghai Stock Exchange, with a total share capital of 137.2 million shares, including 40 million A-shares [3]. - The company does not fall under any prohibitive conditions for implementing stock incentives as outlined in the Management Measures [4]. Group 2: Approval and Authorization - The company has completed the necessary approval and authorization procedures for adjusting the exercise price of the stock options under the 2022 incentive plan, in accordance with the Management Measures and the incentive plan [5][8]. Group 3: Adjustment Details - The exercise price for the stock options has been adjusted from 3.78 yuan to 3.63 yuan per share for the first grant, and from 5.07 yuan to 4.92 yuan per share for the reserved grant, following the company's profit distribution plan [6][8].

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-033 浙江康恩贝制药股份有限公司 关于调整 2022 年股票期权激励计划的股票期权 行权价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司 2022 年股票期权激励计划首次授予的股票期权行权价格由 3.78 元/股调整为 3.63 元/股、预留股票期权授予的行权价格由 5.07 元/股调整为 4.92 元/股。 浙江康恩贝制药股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日召开 第十一届董事会第九次（临时）会议、第十一届监事会第七次（临时）会议分别审 议通过《关于调整 2022 年股票期权激励计划的股票期权行权价格的议案》，根据中 国证监会《上市公司股权激励管理办法》《浙江康恩贝制药股份有限公司 2022 年股 票期权激励计划（草案）》的相关规定以及公司 2022 年第二次临时股东大会有关决 议的授权，同意公司在实施完毕 2024 年度权益分派方案（每 10 股派发现金红利 1.50 元）后，将公司 2022 ...

上海东方华银律师事务所 关于浙江康恩贝制药股份有限公司 2022 年股票期权激励计划行权价格调整事项 之 法律意见书 上海东方华银律师事务所 上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 电话：(8621) 68769686 上海东方华银律师事务所 2022 年股票期权激励计划行权价格调整事项 之法律意见书 关于浙江康恩贝制药股份有限公司 致：浙江康恩贝制药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以下 简称"中国证监会"）发布的《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《国有控股上市公司（境内）实施股权激励试行办法》等有关法 律、法规、规章、规范性文件的规定和《浙江康恩贝制药股份有限公司章程》（以 下简称"《公司章程》"），上海东方华银律师事务所（以下简称"本所"）接 受浙江康恩贝制药股份有限公司（以下简称"康恩贝"或"公司"）的委托，就 公司 2022 年股票期权激励计划（以下简称"本激励计划"）行权价格调整相关 事项出具本法律意见书。 为出具本法律意见书，本所律师特作以下声明： ...

Core Viewpoint - The announcement details the adjustment of the exercise period for the stock options granted under the 2022 stock option incentive plan of Zhejiang Kang En Bei Pharmaceutical Co., Ltd. due to changes in the company's 2024 profit distribution plan [1][2]. Group 1 - The original exercise period was set from May 29, 2025, to June 19, 2025, during which all incentive recipients were restricted from exercising their options [2]. - The adjusted exercise period is now from May 29, 2025, to June 25, 2025, maintaining the restriction on all incentive recipients during this time [2]. - The announcement is made in compliance with the relevant regulations from the China Securities Regulatory Commission and the company's own stock option incentive plan [1].

证券代码：600572 证券简称：康恩贝 公告编号：临2025-032 浙江康恩贝制药股份有限公司 关于2022年股票期权激励计划首次授予股票期权 第一个行权期限制行权期间调整的提示性公告 原定本次限制行权期为2025年5月29日至2025年6月19日，在此期间对全部激 励对象限制行权；因公司2024年度利润分配实施计划时间调整，本次限制行权期 调整为2025年5月29日至2025年6月25日，在此期间对全部激励对象限制行权。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称"公司"）已于2025年5月24日在 《上海证 券报》《中国证券报》 《证券时 报》和上海证券交 易所网站 http://www.sse.com.cn披露了临2025-028号《关于2022年股票期权激励计划首 次授予股票期权第一个行权期限制行权期间的提示性公告》。根据中国证监会《上 市公司股权激励管理办法》《浙江康恩贝制药股份有限公司2022年股票期权激励 计划（草案）》以及中国证券登记结算有限责任公司上海 ...

Core Viewpoint - The company, Zhejiang Kang En Bei Pharmaceutical Co., Ltd., is set to hold a performance briefing on June 18, 2025, to discuss its 2024 annual report and Q1 2025 results, allowing investors to engage and ask questions [2][3][4]. Group 1: Meeting Details - The performance briefing will take place on June 18, 2025, from 13:30 to 14:30 [4]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, with a virtual format combining video and online text interaction [4][5]. - Investors can submit questions from June 11 to June 17, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key attendees from the company include Chairman Jiang Yi, Vice President and CFO Chen Ming, Secretary of the Board Jin Zucheng, and Independent Director Zeng Su [4]. Group 3: Investor Participation - Investors can participate online during the briefing and will receive timely responses to their questions [5]. - The company encourages pre-submission of questions through the designated channels before the event [5]. Group 4: Contact Information - Contact persons for inquiries are Chen Fang and Wang Jie, with provided phone numbers for further assistance [6].